Difference between revisions of "Amitriptyline-clomipramine"

From Psychiatrienet
Jump to: navigation, search
 
(2 intermediate revisions by 2 users not shown)
Line 3: Line 3:
 
| to = clomipramine  
 
| to = clomipramine  
 
| stop =  
 
| stop =  
* Gradually reduce dosage of amitriptyline to a maximum of 50-100 mg/day.
+
{{TCAdecrease25p3d}}
* When a dosage of 50 mg/day is reached, stop administration.
 
 
| start =  
 
| start =  
 
* No wash-out period is needed.  
 
* No wash-out period is needed.  
* Start administration of clomipramine the next day in a normal dosage of 50-75 mg/day.
+
{{TCAincrease25p3d}}
 
| info =
 
| info =
 
* {{TCAantichol}}
 
* {{TCAantichol}}
{{review}}
+
{{TCAplasmalevelmonitoring}}
 
}}
 
}}

Latest revision as of 12:21, 16 June 2016

Amitriptyline
Type Antidepressant
Group TCA
links
ATC-code N06AA09
Medscape Amitriptyline
PubChem 2160
PubMed Amitriptyline
Kompas (Dutch) Amitriptyline
Wikipedia Amitriptyline
Clomipramine
Type Antidepressant
Group TCA
links
ATC-code N06AA04
Medscape Clomipramine
PubChem 2801
PubMed Clomipramine
Kompas (Dutch) Clomipramine
Wikipedia Clomipramine

Switch medication from amitriptyline to clomipramine.

Nietinrijdenbord.png Stop amitriptyline
  • Decrease with about 25% of the original dose per 3 days.
Eenrichtingbord.png Start clomipramine
  • No wash-out period is needed.
  • Increase with about 25% of target dose per 3 days.
Infobord.png More information
  • Both drugs are a TCA with anticholinergic properties, so a switch to a relatively high starting dose can be made.
  • Plasma monitoring for TCA's is advisable, because of plasma-reponse relations, genetic polymorphism and under or overdosing.[1]
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.